ArticleFrontiers in oncology2025
Long-term survival with multidisciplinary treatment in metastatic sarcomatoid renal cell carcinoma: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcomatoid transformation in renal cell carcinoma, termed sarcomatoid renal cell carcinoma (SRCC), is associated with aggressive behavior and an unfavorable prognosis. The presence of sarcomatoid differentiation poses a therapeutic challenge due to limited response to existing systemic therapies; however, advances in drugs with immune checkpoint inhibitor (ICI) have improved response rates. Case description: We report the case of a middle-aged woman diagnosed with multiple metastatic SRCC, treated with a combination of pembrolizumab plus axitinib as first-line therapy, transarterial chemoembolization, and nephrectomy. The patient ultimately achieved complete remission but presented with severe colitis symptoms. Following the cessation of pembrolizumab and axitinib therapy for 1 year, her colitis symptoms gradually resolved, with no evidence of recurrence or metastasis observed during that time. Her survival period has now extended beyond 2.5 years. Conclusion: Metastatic sarcomatoid renal cell carcinoma is associated with very poor prognosis, with a survival period of <1 year despite systemic therapy. In this present case, the patient achieved long-term survival following multidisciplinary treatment-a rare occurrence worthy of report.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.